Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: A cohort study

Aktaş, Mustafa Sinan; Jong, Diederick de; Nuyttens, J.; Zee, Jacoba van der; Wielheesen, D. H. M.; Batman, Erdogan; Burger, Curt W.; Ansink, Anca C.

doi:10.1016/j.ejogrb.2006.05.005

Cited by 23 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HT in combination with other treatments has been considered a promising approach in cancer therapy (3)(4)(5)(6)(7). Thus, the current data will help enable the rational design of more effective strategies for future HT therapy in OSCC cells.…”

Section: Discussionmentioning

confidence: 99%

“…Local hyperthermia (HT) for various malignant tumors including OSCC has been recognized as an effective and attractive tool with the advantages of relatively few side effects and slight damage to normal tissue. Combinations of HT with chemotherapy, radiotherapy or both have been clinically used for patients with cancer in various organs, and their antitumor effects have been verified by many clinical trials (3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gene networks related to the cell death elicited by hyperthermia in human oral squamous cell carcinoma HSC-3 cells

Tabuchi

Wada

Furusawa³

et al. 2011

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Local hyperthermia (HT) for various types of malignant tumors has shown promising antitumor effects. To confirm the detailed molecular mechanism underlying cell death induced by HT, gene expression patterns and gene networks in human oral squamous cell carcinoma (OSCC) cells were examined using a combination of DNA microarray and bioinformatics tools. OSCC HSC-3 cells were treated with HT at 44˚C for 90 min or mild hyperthermia (MHT) at 42˚C for 90 min, followed by culturing at 37˚C for 0-24 h. Treatment of cells with HT prevented cell proliferation (62%) and induced cell death (17%), whereas these alterations were not observed in cells treated with MHT. Microarray analysis revealed substantial differences with respect to gene expression patterns and biological function for the two different hyperthermic treatments. Moreover, we identified the temperature-specific gene networks D and H that were obtained from significantly up-regulated genes in the HT and MHT conditions, respectively, using Ingenuity pathway analysis tools. Gene network D, which contains 14 genes such as ATF3, DUSP1 and JUN, was associated with relevant biological functions including cell death and cellular movement. Gene network H, which contains 13 genes such as BAG3, DNAJB1 and HSPA1B, was associated with cellular function and maintenance and cellular assembly and organization. These findings provide a basis for understanding the detailed molecular mechanisms of cell death elicited by HT in human OSCC cells. IntroductionIn the treatment of oral squamous cell carcinoma (OSCC), treatment outcomes have improved in the past two decades due to progress in reconstructive techniques, stereotactic radiotherapy, new anticancer drugs such as taxanes, and combinations of these therapeutic modalities (1). Nonetheless, it is well known that patients with advanced tumors or tumor recurrence have a poor prognosis with a median survival period less than one year (2). Local hyperthermia (HT) for various malignant tumors including OSCC has been recognized as an effective and attractive tool with the advantages of relatively few side effects and slight damage to normal tissue. Combinations of HT with chemotherapy, radiotherapy or both have been clinically used for patients with cancer in various organs, and their antitumor effects have been verified by many clinical trials (3-7).In general, HT elicits a wide spectrum of stress responses such as induction of heat shock proteins (HSPs), protein aggregation, an imbalance of protein homeostasis, DNA and RNA damage, reactive oxygen species production, cell growth arrest and cell death in mammalian cells (8,9). In particular, HSPs, which are induced by heat, behave as molecular chaperones and exert strong cytoprotective effects that prevent cell death. The treatment of cells with HT induces numerous signal transduction pathways which contribute variously to cell death and survival (10-12). Although many biological processes are affected by HT, the overall responses to HT in mammalian cells remain unknown.Re...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gene networks related to the cell death elicited by hyperthermia in human oral squamous cell carcinoma HSC-3 cells

Tabuchi

Wada

Furusawa³

et al. 2011

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…Vaginal cancers have been chosen as target for HT in small prospective Dutch trial. Patients with vaginal carcinomas with a tumor size larger than 4 cm were treated with RTHT, whereas smaller tumors were primarily treated with RT showing no significant difference in 5y-survival (131). …”

Section: Clinical Evidence Of Combined Thermoradiotherapymentioning

confidence: 99%

Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

2017

View full text Add to dashboard Cite

Hyperthermia (HT) is one of the hot topics that have been discussed over decades. However, it never made its way into primetime. The basic biological rationale of heat to enhance the effect of radiation, chemotherapeutic agents, and immunotherapy is evident. Preclinical work has confirmed this effect. HT may trigger changes in perfusion and oxygenation as well as inhibition of DNA repair mechanisms. Moreover, there is evidence for immune stimulation and the induction of systemic immune responses. Despite the increasing number of solid clinical studies, only few centers have included this adjuvant treatment into their repertoire. Over the years, abundant prospective and randomized clinical data have emerged demonstrating a clear benefit of combined HT and radiotherapy for multiple entities such as superficial breast cancer recurrences, cervix carcinoma, or cancers of the head and neck. Regarding less investigated indications, the existing data are promising and more clinical trials are currently recruiting patients. How do we proceed from here? Preclinical evidence is present. Multiple indications benefit from additional HT in the clinical setting. This article summarizes the present evidence and develops ideas for future research.

show abstract

“…This fact could be explained, at least in part, because cells in the S phase of the cell cycle are relatively resistant to radiation, while being sensitive to the increase in temperature. Hyperthermia represents an effective agent for cell destruction, especially for those cells in hypoxia, in need of nutrients and that are in a low pH environment, characteristics commonly present in malignant tumors [22]. Numerous clinical applications with tissue heating have been identified, including reduction in pain or inflammation and preservation of organs [23].…”

Section: Animals and Experimental Designmentioning

confidence: 99%

Comparative Efficacy of a Biocompatible Citrate-Functionalized Magnetic Fluid Mediating Radiofrequency Hyperthermia and Magnetohyperthermia to Treat Ectopic Ehrlich-Solid-Tumor-Bearing Elderly Mice

Neves¹,

Sousa²,

Vilela³

et al. 2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Objective: We aimed to evaluate the efficacy of a biocompatible citrate-functionalized magnetic fluid (NPCit) sample in mediating hyperthermia, using two types of alternated (AC) magnetic field equipment operating in two different ways: a portable apparatus, generating an electromagnetic field in MHz range (radiofrequency range; radiofrequency hyperthermia-RFHT) developed by our research group (CMagMHG), and a commercial one working in kHz range (magnetohyperthermia-MHT) (Magnetherm, NanoTherics Ltd, Newcastle, United Kingdom), to treat ectopic Ehrlich-solid-tumor-bearing elderly mice. Methods:Females intraperitoneally anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/Kg) were subcutaneously inoculated with Ehrlich ascitic tumor cell suspension (1.03 × 10 6 viable cells) in the upper head region for solid form implantation. After 48 hours, mice received one of four treatments: (a) filtered water and no tumor implantation (negative control); (b) tumor inoculation and no treatment (tumor control); (c) intratumoral injection of NPCit (40 µL) containing 18 × 10 18 particles/mL and 13 minutes' exposure to CMagMHG, operating at 1MHz, 40 Oe field amplitude; (d) intratumoral injection of NPCit and 13 minutes' exposure to Magnetherm, assembled with 17-turn coil, capacitive box B22, operating under 330 kHz, 4.9 A, 25 V and maximum field strength 170 Oe. Treatments occurred once daily for three consecutive days. Tumor histopathology and semi-quantitative analysis of necrosis area served to assess tumor aggressiveness and regression. Possible acute side effects were assessed by animals' body and spleen weight and hemogram.Results: NPcit showed adequate biocompatibility and was effective in mediating RFHT and MHT, which promoted significant increases in necrosis area using both equipment types. Conclusion:Our findings evidence the potential use of NPcit mediating hyperthermia for future use as an adjuvant in breast cancer therapy.

show abstract

Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: A cohort study

Cited by 23 publications

References 17 publications

Gene networks related to the cell death elicited by hyperthermia in human oral squamous cell carcinoma HSC-3 cells

Gene networks related to the cell death elicited by hyperthermia in human oral squamous cell carcinoma HSC-3 cells

Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Comparative Efficacy of a Biocompatible Citrate-Functionalized Magnetic Fluid Mediating Radiofrequency Hyperthermia and Magnetohyperthermia to Treat Ectopic Ehrlich-Solid-Tumor-Bearing Elderly Mice

Contact Info

Product

Resources

About